Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.51 |
| ▸ | DRD2 | P14416 | 8/20 | 0.48 |
| ▸ | DRD3 | P35462 | 5/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28975864 | 0.81 | DRD4 (0.46) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL10819399 | 0.80 | DRD4 (0.54) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL3845634 | 0.78 | DRD4 (0.50) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL21274017 | 0.78 | DRD4 (0.50) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL19117549 | 0.78 | DRD4 (0.50) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL8003967 | 0.77 | DRD4 (0.52) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL7833509 | 0.77 | DRD2 (0.59) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL6195713 | 0.77 | DRD4 (0.59) | DRD4DRD2DRD3 | |
| SCHEMBL8844465 | 0.76 | PDCD1LG2 (0.52) | DRD4DRD2DRD3PDCD1LG2CD274 | |
| SCHEMBL14868702 | 0.76 | PDCD1LG2 (0.52) | DRD4DRD2DRD3PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8853408-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| CN-103857393-A | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE LLC | 2014-06-11 | — | — | CN | disclosed |
| EP-2688568-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-29 | — | — | EP | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2012135113-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | DRD4 3828/4885DRD2 3467/4885DRD3 3835/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | DRD4 3828/4885DRD2 3467/4885DRD3 3835/4885 |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | DRD4 3828/4885DRD2 3467/4885DRD3 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.